Læs om de seneste fremskridt inden for ALS-behandling og bevidsthedskampagner i kampen mod sygdommen!
Universitetet i Illinois registrerede taleprojekt, der rekrutterer ALS-patienter til en spændende undersøgelse. Immunity Pharma forbereder sig til en afgørende prøve med deres ALS-medicin efter positive resultater fra fase IIa. Progressionen af ALS er blevet forbundet til en membran og et enzym, hvilket har afgørende betydning for patienters motoriske neuroners toleranceniveau. På Jersey Shore University Medical Center tilbydes ALS-patienter topkvalitetsbehandling som en af kun to nationale certificerede behandlingscentre i New Jersey. Stem celle-baseret terapi for ALS er blevet vurderet som sikker i fase 2-studier, og forskning viser en sammenhæng mellem ALS progression og mitokondrie-associeret membran-ER. Disse nyskabende fremskridt og samarbejder i kampen mod ALS lover håb for patienterne og bidrager til den fortsatte forskning og bevidsthed om sygdommen.
The Speech Accessibility Project run by a university institute aims to better train, broaden range of assistive speech devices patients use.
The teams' two matchups this season will serve as the first initiative of its kind, with the intention of promoting ALS awareness and research. “We actually ...
The Phase IIa results of IPL344 gives the company confidence to progress to a pivotal trial of the candidate in ALS.
Immunity Pharma Announces Positive Top Line Results from Phase 2a Trial with IPL344 in ALS Patients - read this article along with other careers information ...
Research revealed that diminished activities of an enzyme called TBK1 in mitochondrial-associated membrane (MAM) reduces motor neurons' tolerance to ...
“Jersey Shore's ALS Center is one of only two nationally Certified Treatment Centers of Excellence in New Jersey, as designated by the ALS Association,” Dr.
The demands of ALS care often leave little room for error, and making mistakes can be costly, columnist Kristin Neva writes.
CL2020, an investigational stem cell-based therapy, was found to be safe in five people with ALS who took part in a Phase 2 clinical study.
Researchers at Nagoya University in Japan have discovered a relationship between the progression of amyotrophic lateral sclerosis (ALS), also known as Lou ...